First National Advisers Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$801K |
| 2 |
InMode
INMD
|
+$412K |
| 3 |
Abbott
ABT
|
+$402K |
| 4 |
Robert Half
RHI
|
+$266K |
| 5 |
Comcast
CMCSA
|
+$266K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$749K |
| 2 |
Corpay
CPAY
|
+$635K |
| 3 |
LHCG
LHC Group LLC
LHCG
|
+$622K |
| 4 |
AMN Healthcare
AMN
|
+$407K |
| 5 |
KeyCorp
KEY
|
+$212K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.82% |
| 2 | Healthcare | 14.18% |
| 3 | Financials | 12.71% |
| 4 | Industrials | 10.23% |
| 5 | Consumer Discretionary | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Diamondback Energy
FANG
$56B
| $227K | 0.26% |
1,676
+30
| +2% | +$4.18K |
|
102
Intercontinental Exchange
ICE
$85.2B
| $226K | 0.26% |
2,166
+218
| +11% | +$22.7K |
|
103
Lockheed Martin
LMT
$134B
| $219K | 0.25% |
464
+42
| +10% | +$19.7K |
|
104
Roper Technologies
ROP
$38.9B
| $219K | 0.25% |
+497
| New | +$215K |
|
105
Travelers Companies
TRV
$78.1B
| $208K | 0.24% |
1,211
+73
| +6% | +$13.3K |
|
106
Amgen
AMGN
$205B
| $202K | 0.23% |
837
-160
| -16% | -$39.3K |
|
107
Duke Energy
DUK
$97.2B
| $201K | 0.23% |
2,088
+67
| +3% | +$6.62K |
|
108
Target
TGT
$67.6B
| $201K | 0.23% |
+1,214
| New | +$200K |
|
109
RPM International
RPM
$13.9B
| $200K | 0.23% |
2,294
+117
| +5% | +$10.2K |
|
|
110
AMN Healthcare
AMN
$1.33B
| – | – |
-3,963
| Closed | -$407K |
|
|
111
KeyCorp
KEY
$24.3B
| – | – |
-12,166
| Closed | -$212K |
|
|
112
Corpay
CPAY
$25.1B
| – | – |
-3,459
| Closed | -$635K |
|
|
LHCG
113
DELISTED
LHC Group LLC
LHCG
| – | – |
-3,846
| Closed | -$622K |
|
Similar funds
First National Advisers's Q1 2023 Portfolio in Review
As of Q1 2023, First National Advisers held 114 positions worth $88.2M, up 13% from $78.1M the previous quarter. Its ten largest holdings account for 28% of the portfolio.
First National Advisers deployed $4.72M of net new capital in Q1 2023, opening 6 new positions and adding to 84 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 5,416 shares worth $793K.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $749K trimmed.
- First National Advisers's largest Q1 2023 buy was Jazz Pharmaceuticals: 5,416 shares worth $793K.
- First National Advisers added most to Abbott in Q1 2023, an estimated $402K increase.
- First National Advisers's biggest Q1 2023 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $749K.
- First National Advisers fully exited Corpay in Q1 2023, selling an estimated $635K.
- First National Advisers's ten largest holdings make up 28% of its $88.2M portfolio in Q1 2023.
- First National Advisers opened 6 new positions and closed 4 in Q1 2023.
- First National Advisers's portfolio value rose 13% quarter-over-quarter to $88.2M.
Based on First National Advisers's 13F filing for Q1 2023, filed 10 May 2023.